Safest Antipsychotic and Antidepressants in First Trimester
For antidepressants in the first trimester, sertraline is the safest choice, while paroxetine and fluoxetine should be avoided due to increased risk of cardiac malformations. For antipsychotics, olanzapine, quetiapine, or risperidone (with caution) are reasonable options, though data remain limited 1, 2.
Antidepressants: Specific Recommendations
First-Line Choice: Sertraline
- Sertraline has no evidence of increased cardiac malformations and is one of the most commonly prescribed antidepressants during pregnancy 3
- Recent meta-analyses show no link between first-trimester sertraline use and cardiac defects, unlike other SSRIs 3
- Also preferred for breastfeeding 4
Avoid These Agents:
- Paroxetine: FDA pregnancy category D since 2005; suggestive evidence shows increased risk of cardiac malformations (1.28 [1.11-1.47]) and major congenital malformations (1.24 [1.09-1.40]) 5, 3
- Fluoxetine: Evidence shows increased risk of congenital heart defects 3
Alternative Consideration:
- Bupropion: Does not appear associated with major congenital malformations overall, though some studies suggest small absolute increases in left ventricular outflow tract obstruction and ventricular septal defects (aOR 2.9; 95% CI 1.5-5.5), with conflicting evidence and possible confounding 6
Antipsychotics: Specific Recommendations
Reasonable First-Line Options:
The most commonly used and studied antipsychotics are olanzapine, quetiapine, and risperidone 1, 2:
- Olanzapine and Quetiapine: No consistent evidence of congenital malformations or specific patterns of fetal harm 1, 2
- Risperidone: Use with caution as there is "possible exception" regarding malformation risk; not considered first-line 1
Important Caveats for All Antipsychotics:
- Monitor for gestational diabetes - atypical antipsychotics show association with this outcome 1, 2
- Be aware of potential neonatal respiratory distress and withdrawal symptoms 2
- Most studies suggest antipsychotics as a class appear safe regarding teratogenicity in monotherapy 7
- A 2025 umbrella review found no convincing or highly suggestive evidence of adverse outcomes with psychotropic use in pregnancy, though quality of evidence was limited 5
Critical Clinical Context
The Untreated Illness Risk:
Depression during pregnancy is associated with premature birth and decreased breastfeeding initiation 4. Untreated severe psychiatric illness poses substantial risks that may outweigh medication risks 8, 7.
Evidence Quality Warning:
The overall methodological quality of pregnancy safety studies is low (AMSTAR-2 score 54.8%), with high risk of indication bias - meaning the underlying psychiatric condition itself may cause adverse outcomes attributed to medications 3. Most effect sizes are small except for neonatal adaptation symptoms 3.
Decision Algorithm:
- Mild depression, recent onset (≤2 weeks): Monitor, encourage exercise and social support
- Mild depression not improving after 2 weeks OR moderate-to-severe depression: Evidence-based treatment needed
- Severe depression with history of suicide attempts or previous relapse when stopping medication: Continue antidepressants during pregnancy 8
- For psychotic disorders requiring antipsychotics: Continue the agent that has been most effective for symptom remission, preferably olanzapine or quetiapine 1